A novel algorithm for analyzing drug-drug interactions from MEDLINE literature

Yin Lu¹, Dan Shen², Maxwell Pietsch³, Chetan Nagar¹, Zayd Fadli⁴, Hong Huang⁵, Yi-Cheng Tu³, Feng Cheng^{1,6,*}

¹Department of Pharmaceutical Science, College of Pharmacy, University of South Florida, Tampa, FL, 33612, USA

²Department of Mathematics & Statistics, University of South Florida, Tampa, FL, 33612, USA ³Department of Computer Science and Engineering, University of South Florida, Tampa, FL, 33612, USA

⁴College of Medicine, Syrian private university, Damascus, 0100, Syria

⁵School of Information, University of South Florida, Tampa, FL, 33612, USA

⁶Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa 33612, USA

*Correspondence and requests for materials should be addressed to F. C. (email: fcheng1@health.usf.edu)

Drug-drug interaction (DDI) is becoming a serious clinical safety issue as the use of multiple medications becomes more common. Searching the MEDLINE database for journal articles related to DDI produces over 330,000 results. It is impossible to read and summarize these references manually. As the volume of biomedical reference in the MEDLINE database continues to expand at a rapid pace, automatic identification of DDIs from literature is becoming increasingly important. In this article, we present a random-sampling-based statistical algorithm to identify possible DDIs and the underlying mechanism from the substances field of MEDLINE records. The substances terms are essentially carriers of compound (including protein) information in a MEDLINE record. Four case studies on warfarin, ibuprofen, furosemide and sertraline implied that our method was able to rank possible DDIs with high accuracy (90.0% for warfarin, 83.3% for ibuprofen, 70.0% for furosemide and 100% for sertraline in the top 10% of a list of compounds ranked by p-value). A social network analysis of substance terms was also performed to construct networks between proteins and drug pairs to elucidate how the two drugs could interact.

Drug-drug interaction (DDI) is typically defined as a change in the effect of a drug when it is taken together with another drug. A DDI may involve an increase in the action of either drug, a decrease in drug efficacy, a delay in drug absorption rate, or an unexpected harmful side effect. DDI incidence increases as the simultaneous use of multiple drugs becomes more common¹⁻³. Centers for Disease Control (CDC) reported that the percentage of the U.S. population taking three or more prescription drugs increased from 11.8% in 1988-1994 to 20.8% in 2007-2010, and the percentage of people taking five or more drugs increased from 4.0% to 10.1% during this same time period⁴. DDIs are a major cause of morbidity and mortality and lead to increased health care costs. DDIs make up nearly 3% of all hospital admissions⁵ and 3% to 5% of all inpatient medication errors⁶. DDIs directly. Serious interactions are often discovered after a drug is already on the market for a long time⁷. Therefore, Identification of possible DDIs is very important for drug development and clinical patient care.

The experimental approaches in characterizing DDIs, e.g. *in vitro*⁸, *in vivo*⁹, and *in populo*¹⁰, are performed at a relatively small scale. Computational methods provide the opportunity to conduct large-scale studies on DDIs. Thus far, computational solutions to predict DDIs have consisted of two distinct approaches: 1) Similarity-based approaches that measure the similarity of drug information. Previous methods were originally designed to infer novel potential targets of drugs based on various type of data, such as molecular structures^{11,12}, targets^{13,14}, indications¹⁵, side-effects¹⁶ and gene expression profiles¹⁷. These methods can be used to infer drug interactions. 2) Knowledge-based approaches that predict DDI from scientific literature (biomedical abstracts)¹⁸⁻²², an electronic medical record database²³ and the FDA Adverse Event Reporting System²⁴, where text mining presents a solution to the problem of uncovering novel DDIs.

DDIs are frequently reported in clinical and scientific journals. Therefore, literature is the most useful and comprehensive resource for the DDI detection. MEDLINE (Medical Literature Analysis and Retrieval System Online) developed by the U.S. National Library of Medicine (NLM), is the most widely used database of life sciences and biomedical literature. MEDLINE contains over 24 million entries from more than 5,600 journals, with 2,000-4,000 new references being added daily. A MEDLINE search for journal articles related to DDI currently produces more than 330,000 results. Though this gigantic amount of MEDLINE literature pertaining to DDI offers an unprecedented opportunity for the study of drug-drug interaction, it is impossible to identifying DDI information from these references manually. High throughput, accurate, reliable and user-friendly retrieval of DDI information is in increasing demand.

Generally, a MEDLINE record representing one journal article is composed of the some fields including title of the journal article, author information, journal information, publication type, language, abstract, MeSH terms (Medical Subject Headings), and substances. Recently published research has focused on information extraction from abstract¹⁸⁻²². In our study we chose the substances field to investigate DDIs because the field of MEDLINE records contains a bounty of useful information of compounds and proteins. These terms in the substances field are essentially carriers of a documents' information. The Substances terms of MEDLINE records are generally manually indexed by specialized personnel, which makes the information more reliable. To our knowledge, no studies have been performed to investigate DDIs using substances terms from MEDLINE.

Our strategy was to use a random-sampling-based statistical algorithm to compare the cooccurrence of substances with the drug of interest in MEDLINE records containing the keyword "drug interactions" and those in records without "drug interactions". Four case studies on warfarin, ibuprofen, furosemide and sertraline implied that our method was able to rank possible DDIs with high accuracy. In addition to identifying possible DDIs, the algorithm indicated proteins that may participate in those DDIs. Social network analysis was also performed to construct networks between proteins and drug pairs to elucidate the possible mechanism of DDIs.

RESULTS

Identification of the drug pairs with DDIs. For ibuprofen, warfarin, furosemide and sertraline, there are 500, 2013, 650 and 299 articles with DDI-related MeSH terms in the MEDLINE database, respectively. Then, 916, 1364, 932 and 496 candidate substances were identified from the related articles. The cutoff value of compound pair frequency was set at 3, which means that if the frequency of candidate compound was less than 3, the candidate was not considered for further analysis. Our random-sampling-based algorithm showed that the co-occurrences of 39, 161, 62, and 29 chemicals with the corresponding drugs in articles with drug-interactions were significantly higher than in articles without drug-interactions (p < 0.1). As shown in **Table 1**, in the top 10 compounds identified by our algorithm, 8, 10, 7, 9 compounds were shown to interact with ibuprofen, warfarin, furosemide and sertraline respectively. These four examples show that our algorithm can correctly identify most of DDIs.

As shown in **Figure 1**, the random sampling step in our algorithm improved accuracy of identification. For example, with such a step, our algorithm ranked DDIs with a high accuracy (90% for warfarin, 83.3% for ibuprofen, 70.0% for furosemide and 100% for sertraline in the top 10% of predicted chemical list, shown in black bars in **Figure 1**). However, the accuracy (grey bars) was 85.0% for warfarin, 50.0% for ibuprofen, 60.0% for furosemide and 50.0% for sertraline in the top 10% of compounds identified by co-occurrence without random sampling. The accuracy (white bars) was only 78.3% for warfarin, 42.9% for ibuprofen, 50.0% for furosemide and 60.0% for sertraline in the top 10% of compounds identified by only frequency. The results prove the effectiveness of the random sampling step to filter irrelevant substances terms.

Analysis of the proteins involved DDIs. Understanding the drug-protein-drug interactions is key in exploring the action mechanism of DDIs. Besides identifying compound pairs that may interact, we also investigated the possible mechanism of DDIs by analyzing the protein information from the substances field of MEDLINE records. Statistically significant proteins from the substances terms were identified using the same random-sampling-based approach. Significant proteins of ibuprofen, warfarin, furosemide and sertraline were shown in **Table 2**. PTGS1 protein, CYP2C9 and Aryl Hydrocarbon Hydroxylases were identified for ibuprofen. Among them, PTGS1 and CYP2C9 have been shown to be related to DDIs involving ibuprofen. Ibuprofen is a substrate of the hepatic cytochrome isoenzyme CYP2C9²⁵. Inhibiting CYP2C9 by other compounds may lead to increased plasma concentrations of ibuprofen²⁶. In addition, the adverse gastrointestinal (GI) effects caused by the nonsteroid anti-inflammatory drugs (NSAID) are associated with inhibition of PTGS1²⁷. Because ibuprofen exerts similar pharmacologic characteristics to other systemic nonsteroidal antiinflammatory drugs (NSAIDs), additive pharmacodynamic effects, including a potential increase for additive adverse gastrointestinal (GI) effects caused with other NSAIDs²⁸.

For warfarin, several cytochrome P-450 (CYP) isoenzymes (including CYP3A4, CYP1A2, CYP2D6 and CYP2C9), steroid 16-alpha-hydroxylase, steroid hydroxylases, aryl hydrocarbon hydroxylases, alanine transaminase, aspartate aminotransferases, PTGS2 and prostaglandinendoperoxide synthases were identified as statistically significant proteins. Warfarin is stereoselectively metabolized by hepatic cytochrome P-450 (CYP) isoenzymes to inactive, hydroxylated metabolites (predominant route) and by reductases to reduced metabolites (warfarin alcohols). Inhibiting these cytochrome P-450 (CYP) isoenzymes by other compounds may increase or decrease the metabolism of warfarin leading to altered anticoagulation effects²⁹. The CYP isoenzymes involved in the metabolism of warfarin include 2C9, 2C19, 2C8, 2C18, 1A2, and 3A4^{28,30-32}. CYP2C9 is the principle enzyme that metabolizes S-warfarin and modulates the in vivo activity of warfarin. The R-isomer is metabolized by CYP1A2 and CYP3A4, and to a lesser extent by CYP2C19.

For furosemide, Thromboxane-A Synthase and Glutathione Transferase were identified. Thromboxane-A synthase inhibition can enhance furosemide-induced renal vasodilation³³. The activity of Glutathione Transferase might be modified after the interaction between furosemide and sulforaphane, and this may lead to drug effectiveness alternation³⁴.

For sertraline, several cytochrome P-450 (CYP) isoenzymes (including CYP2D6, CYP2C9, CYP1A2, CYP2C19), Mixed Function Oxygenases, Steroid 16-alpha-Hydroxylase, Steroid Hydroxylases, Aryl Hydrocarbon Hydroxylases and Receptor, Serotonin, 5-HT1A were identified. *In vitro* data suggest sertraline is a substrate of CYP2B6, CYP2C9, CYP2D6, CYP3A4, and CYP2C19³⁵. Inhibiting these cytochrome P-450 (CYP) isoenzymes may increase or decrease the metabolism of sertraline leading to increased serum concentrations and possible toxicity³⁶. In addition, antagonizing serotonin (5-HT) receptors could oppose the pharmacologic actions of sertraline³⁷. These four case studies show that our algorithm can correctly identify most of DDI-related proteins.

Constructing networks between proteins and drug pairs. In this study, the relationships between proteins and drugs were modeled using social network analysis. We inferred that the proteins linking drug pairs might take part in the DDIs of the pair. For example, as shown in Figure 2B, CYP2C9 acted as a link between fluoxetine and warfarin. In clinical studies, combining fluoxetine and warfarin may further increase the risk of bleeding by inhibiting warfarin's CYP2C9 metabolism³⁸. Bosentan interacted with warfarin with CYP2C9 and CYP3A4 as connective nodes. Coadministration of bosentan 500 mg twice daily for 6 days decreases the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29% and 38%, respectively³⁹ The networks will not only show which proteins are more important for DDIs but also provide some mechanistic illuminations. The mechanisms of DDIs may be classified into pharmacokinetic and pharmacodynamic². Pharmacokinetic DDIs occur when one drug influences the ADMET (absorption, distribution, metabolism, or excretion) of another. Pharmacodynamic DDI occur when both drugs act at the same biological target/pathway resulting in synergistic or antagonistic effects. From the constructed network, we find that the DDI-related proteins for warfarin are metabolism-related (such as CYP2C9, CYP3A4, and CYP1A2) and infer that the warfarin involved DDIs are mainly pharmacokinetic.

DISCUSSION

In this paper we presented a novel algorithm to facilitate knowledge discovery of DDIs by exploring existing high quality information that was manually complied into substances fields in MEDLINE literature. By using a random sampling step our method has the advantage of eliminating irrelevant terms, yielding a high accuracy compared to ranking strategies based on term frequency and term pair co-occurrence without random sampling. In addition, our method appeared to be capable of identifying proteins and networks involved in DDIs, shedding light on potential DDI mechanisms. There are many studies for MEDLINE data mining. Our study innovates in the following ways:

1. Recently published research has focused on information extraction from abstract. We focus on substances terms in MEDLINE databases in this paper. Substance is chosen to investigate DDIs because the field of MEDLINE records contains a lot of useful chemical information including MeSH chemical and drug terms, protocol terms and non-MeSH rare disease terms from the NIH Office of Rare Diseases. The substances terms of MEDLINE records

are generally indexed by specialized personnel, which makes the information more reliable. To our knowledge, no studies have been performed to investigate DDIs using substances terms.

2. For four example compounds, the random sampling step in our algorithm yields a higher overall identification accuracy than methods done without random sampling or methods based on frequency only.

3. Our algorithms not only identify possible DDI events but also predict the mechanism by which two (or more) drugs interact. No algorithm is available for identifying the proteins potentially involved in DDIs from MEDLINE database.

In summary, we believe our algorithm will improve the ability of the research community to efficiently use large and complex MEDLINE data. As the number of records in the MEDLINE database continues to grow, our algorithm will become increasingly vital for DDI studies.

There are some limitations of the proposed algorithm. Information in substances fields is compiled manually, some information is inevitably missing and this is an obstacle for higher recall. Some low-frequency terms were excluded at the cutoff of 3, which may have resulted in lower recall. However, as more and more references are added to MEDLINE, the impact of these factors will be improved in the future. In addition, some mechanism-related information can be summarized in the text of the abstract of articles. Therefore, a text-mining algorithm will be developed in subsequent research to automate extraction of specific information such as, compounds, genes (or proteins) and their associations from the Abstract field of MEDLINE records.

A web service, DDIRANK, will be developed implementing the statistical algorithms described in this paper. Users will query DDIRANK by drug/compound name and view analyzed information from MEDLINE. The service will be freely accessible and support all common Internet browsers. It will be a valuable tool for clinical pharmacists and basic scientists to analyze DDIs in a reliable way.

Generally, the DDIRANK system is an implementation of algorithms that extract substances from MEDLINE records and then probabilistically score and rank these terms. The DDIRANK system will include two components:

1) DDI_extract. The main function of DDI_extract is to extract substances from MEDLINE records. Users can submit analysis queries through the web interface by inputting a compound name. The compound name and its synonym will be used to build a query to search MEDLINE database through the PubMed search engine. All MEDLINE records containing the queried compound will be downloaded. Substances of the retrieved records will then be extracted and stored in a pre-established MySQL database. 2) DDI_substance. The function of DDI_substance is to identify the most reliable DDI-related substance information from the DDI_extract using the random-sampling-based approach shown in this paper. The p-value can rank the extracted substances and filter the terms that are not related to DDIs.

The web service will be developed following a 3-tier design: users can submit analysis queries through the web interface; the queries will be processed using PHP (middle-tier, application server based on Apache) against a MySQL relational database (back-end, database server). The result of each query is presented to the user in the web browser or through email. The results of any query can be exported to various popular file formats such as CSV and PDF.

METHODS

Identification of DDI-related compounds or proteins from substances of MEDLINE. Our proposed algorithm contains the three steps shown in Figure 3. In the first step, we searched PubMed for the name of the drug and downloaded the resulting articles from MEDLINE. The text in the PubMed IDs (PMIDs), title, abstract, substances and MeSH terms fields of these articles was extracted, excluding those articles that lacked MeSH terms. The remaining articles were

separated into two groups: articles containing the DDI-related MeSH terms (Group A) and articles without DDI-related MeSH terms (Group B). Here, DDI-related MeSH terms include 'drug interactions', 'drug agonism', 'drug partial agonism', 'drug antagonism', 'drug inverse agonism', 'drug synergism', 'food-drug interactions', and 'herb-drug interactions'. A list of all the compounds and proteins in the substances field of articles in group A was created. From here on we will refer to members of this list as 'candidates' and the co-occurrence of a member of this list, either a compound or protein, with the queried drug that was searched for on PubMed, as a 'term pair'. Then the number of articles that contained a term pair was counted. We set cutoff value of compound pair frequency at 3, meaning that if the frequency of term pairs in group A was selected based on the balance of accuracy and the numbers of candidates. As shown in **Supplementary Figure 1**, with the augment of cutoff, the area under the curve (AUC) increases, while the number of obtained compounds decreases.

Generally, because the articles in group A have DDI-related Mesh terms, we believed the number of compounds and proteins in group A involved in DDIs would naturally be larger than the number of DDI-related compounds and proteins in group B. However, the candidate list derived from the first step contained false positives that were unrelated to DDIs. Therefore, an important task was the exclusion of false positive candidates. In the second step, we compared the number of the term pairs in the substances field of group A with the number of the term pairs in the substances field of group B using random sampling analysis. During this step, the number of articles selected from group B was equal to the number of articles that had been selected from group A. The number of term pairs in group B was calculated. The process was repeated many times (for example, 100 times) to establish the null distribution of the term pairs in the articles without DDIs.

In the third step, the p-value for each candidate compound or protein was calculated based on the distribution identified in step two. Co-occurrences of protein or compound with queried drugs are integers and we made the assumption that the co-occurrences followed a normal distribution. The co-occurrences of a term pair were set as x0 (in group A), and $x_1, x_2, x_3...x_{100}$, (100 times in group B) respectively. Null hypothesis H of testing was that x0 has the same distribution with $\{x_1, x_2, x_3...x_{100}\}$. The p-value was defined as the probability for a right tail event under the assumption of H. The formula used to calculate the p-value was $p = P(x>x_0)$. In practice, there occurred a special situation in the distribution $\{x_1, x_2, x_3...x_{100}\}$ of $x_1 = x_2 = x_3 = ... = x_{100} = 0$. In this case, p was set to 0 and the larger x0 was, the higher the corresponding candidate compound or protein was ranked. Statistical significance level was set to 0.1. A p-value less than 0.1 indicated that the number of the term pairs in articles with DDIs (group A) was significantly higher than that in articles with DDIs (group B).

Social network analysis. Social network analysis was applied to explore the connections among drug pairs and significant protein terms. Social network analysis is a strategy for characterizing networked structures in terms of nodes (compounds or proteins) and edges (interactions) using graph theory⁴⁰. The term pairs whose p-value < 0.1 and corresponding co-occurrence counts ≥ 3 were selected to build a network using package igraph in R. The terms and articles were considered as people and groups in a social network. The term-article matrix was then taken as the group membership of people.

Algorithm Validation. We chose four medications, ibuprofen, warfarin, furosemide and sertraline to demonstrate the applicability of our method by validating our DDI predictions against a gold standard. DDI information for these two compounds was collected from LexiComp (<u>http://online.lexi.com</u>), Clinical Pharmacology (<u>http://clinicalpharmacology-ip.com</u>), Drug InteractionChecker (<u>http://www.drugs.com/drug_interactions.php</u>), and Micromedex

(http://micromedex.com) databases as a gold standard for validation. Ibuprofen is considered to be among the safest nonsteroidal anti-inflammatory drug with few side effects, however, combining ibuprofen with some medications, such as aspirin increases the risk of certain side effects. Warfarin is an anticoagulant used in the treatment of thrombosis. Warfarin can have dangerous side effects (for example bleeding) from interacting with certain medicines or even with food. Furosemide is a loop diuretic that inhibits sodium and chloride reabsorption. Some of the drug interactions with furosemide can potentially lead to hearing loss, extremely low blood pressure, or low potassium levels. Sertraline is a selective serotonin reuptake inhibitor commonly used to treat anxiety disorders and major depression. Several potential drug interactions with sertraline can cause symptoms of serotonin syndrome, which can be very dangerous.

ACKNOWLEDGEMENTS

The project was supported by the University of South Florida (USF) Research start-up grant. Y. Tu is supported by a grant (R01GM086707) from National Institutes of Health (NIH), USA.

REFERENCES

- 1 Linda Brewer, D. W. Drug interactions that matter. *Clinical pharmacology* **40**, 371-375 (2012).
- 2 Writers, A. M. Drug interactions result from a number of underlying pharmacokinetic and pharmacodynamic mechanisms. *Drugs & Therapy Perspectives* **29**, 217-222 (2013).
- 3 Zhang, L., Reynolds, K. S., Zhao, P. & Huang, S. M. Drug interactions evaluation: an integrated part of risk assessment of therapeutics. *Toxicology and applied pharmacology* 243, 134-145, doi:10.1016/j.taap.2009.12.016 (2010).
- 4 Percha, B. & Altman, R. B. Informatics confronts drug-drug interactions. *Trends in pharmacological sciences* **34**, 178-184, doi:10.1016/j.tips.2013.01.006 (2013).
- 5 Jankel, C. A. & Fitterman, L. K. Epidemiology of drug-drug interactions as a cause of hospital admissions. *Drug safety* **9**, 51-59 (1993).
- 6 Leape, L. L. *et al.* Systems analysis of adverse drug events. ADE Prevention Study Group. *Jama* **274**, 35-43 (1995).
- 7 Corrigan, O. P. A risky business: the detection of adverse drug reactions in clinical trials and postmarketing exercises. *Social science & medicine* **55**, 497-507 (2002).
- Huang, S. M. *et al.* New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. *Journal of clinical pharmacology* 48, 662-670, doi:10.1177/0091270007312153 (2008).
- Quinney, S. K. *et al.* Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. *Drug metabolism and disposition: the biological fate of chemicals* 38, 241-248, doi:10.1124/dmd.109.028746 (2010).
- 10 Schelleman, H. *et al.* Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. *Clinical pharmacology and therapeutics* **84**, 581-588, doi:10.1038/clpt.2008.150 (2008).
- 11 Vilar, S. *et al.* Drug-drug interaction through molecular structure similarity analysis. *Journal of the American Medical Informatics Association : JAMIA* **19**, 1066-1074, doi:10.1136/amiajnl-2012-000935 (2012).
- 12 Vilar, S., Uriarte, E., Santana, L., Tatonetti, N. P. & Friedman, C. Detection of drug-drug interactions by modeling interaction profile fingerprints. *PloS one* 8, e58321, doi:10.1371/journal.pone.0058321 (2013).
- 13 Keiser, M. J. *et al.* Predicting new molecular targets for known drugs. *Nature* **462**, 175-181, doi:10.1038/nature08506 (2009).

- 14 Yildirim, M. A., Goh, K. I., Cusick, M. E., Barabasi, A. L. & Vidal, M. Drug-target network. *Nature biotechnology* **25**, 1119-1126, doi:10.1038/nbt1338 (2007).
- 15 Berger, S. I. & Iyengar, R. Network analyses in systems pharmacology. *Bioinformatics* **25**, 2466-2472, doi:10.1093/bioinformatics/btp465 (2009).
- 16 Campillos, M., Kuhn, M., Gavin, A. C., Jensen, L. J. & Bork, P. Drug target identification using side-effect similarity. *Science* **321**, 263-266, doi:10.1126/science.1158140 (2008).
- 17 Lamb, J. *et al.* The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. *Science* **313**, 1929-1935, doi:10.1126/science.1132939 (2006).
- 18 Tari, L., Anwar, S., Liang, S., Cai, J. & Baral, C. Discovering drug-drug interactions: a textmining and reasoning approach based on properties of drug metabolism. *Bioinformatics* 26, i547-553, doi:10.1093/bioinformatics/btq382 (2010).
- 19 Percha, B., Garten, Y. & Altman, R. B. Discovery and explanation of drug-drug interactions via text mining. *Pacific Symposium on Biocomputing*. *Pacific Symposium on Biocomputing*, 410-421 (2012).
- 20 Segura-Bedmar, I., Martinez, P. & de Pablo-Sanchez, C. A linguistic rule-based approach to extract drug-drug interactions from pharmacological documents. *BMC bioinformatics* **12 Suppl 2**, S1, doi:10.1186/1471-2105-12-S2-S1 (2011).
- 21 Yan, S., Jiang, X. & Chen, Y. Text Mining Driven Drug-Drug Interaction Detection. Proceedings. IEEE International Conference on Bioinformatics and Biomedicine, 349-355, doi:10.1109/BIBM.2013.6732517 (2013).
- 22 Wang, Z. *et al.* Literature mining on pharmacokinetics numerical data: a feasibility study. *Journal of biomedical informatics* **42**, 726-735, doi:10.1016/j.jbi.2009.03.010 (2009).
- 23 Duke, J. D. *et al.* Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions. *PLoS computational biology* **8**, e1002614, doi:10.1371/journal.pcbi.1002614 (2012).
- 24 Tatonetti, N. P., Ye, P. P., Daneshjou, R. & Altman, R. B. Data-driven prediction of drug effects and interactions. *Science translational medicine* **4**, 125ra131, doi:10.1126/scitranslmed.3003377 (2012).
- 25 Hamman, M. A., Thompson, G. A. & Hall, S. D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. *Biochemical pharmacology* **54**, 33-41 (1997).
- 26 Hynninen, V. V. *et al.* Effects of the antifungals voriconazole and fluconazole on the pharmacokinetics of s-(+)- and R-(-)-Ibuprofen. *Antimicrobial agents and chemotherapy* 50, 1967-1972, doi:10.1128/AAC.01483-05 (2006).
- Warner, T. D. *et al.* Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.
 Proceedings of the National Academy of Sciences of the United States of America 96, 7563-7568 (1999).
- 28 Havrda, D. E., Mai, T. & Chonlahan, J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. *Pharmacotherapy* 25, 303-307, doi:10.1592/phco.25.2.303.56955 (2005).
- 29 Greenblatt, D. J. & von Moltke, L. L. Interaction of warfarin with drugs, natural substances, and foods. *Journal of clinical pharmacology* **45**, 127-132, doi:10.1177/0091270004271404 (2005).
- 30 Sanderson, S., Emery, J. & Higgins, J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. *Genetics in medicine :* official journal of the American College of Medical Genetics **7**, 97-104, doi:10.109701.GIM.0000153664.65759.CF (2005).
- 31 Yin, T. & Miyata, T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 rationale and perspectives. *Thrombosis research* **120**, 1-10, doi:10.1016/j.thromres.2006.10.021 (2007).
- 32 Ageno, W. *et al.* Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141, e44S-88S, doi:10.1378/chest.11-2292 (2012).
- 33 Wilson, T. W., Badahman, A. H. & Kaushal, R. D. Thromboxane synthase inhibition enhances furosemide-induced renal vasodilation. *Clin Invest Med* **16**, 372-378 (1993).

- 34 Lubelska, K. *et al.* Interactions between drugs and sulforaphane modulate the drug metabolism enzymatic system. *Pharmacol Rep* **64**, 1243-1252 (2012).
- 35 Obach, R. S., Cox, L. M. & Tremaine, L. M. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. *Drug metabolism and disposition: the biological fate of chemicals* 33, 262-270, doi:10.1124/dmd.104.002428 (2005).
- 36 Preskorn, S. H., Alderman, J., Greenblatt, D. J. & Horst, W. D. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. *Psychopharmacol Bull* 33, 659-665 (1997).
- 37 Horowitz, B. Z. & Mullins, M. E. Cyproheptadine for serotonin syndrome in an accidental pediatric sertraline ingestion. *Pediatr Emerg Care* **15**, 325-327 (1999).
- 38 Sayal, K. S., Duncan-McConnell, D. A., McConnell, H. W. & Taylor, D. M. Psychotropic interactions with warfarin. *Acta psychiatrica Scandinavica* **102**, 250-255 (2000).
- 39 Hardy, H., Backman, E. S. & Farber, H. W. Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. *Pharmacotherapy* **30**, 139e-144e, doi:10.1592/phco.30.4.422 (2010).
- 40 Newman, M. E. J. The Structure and Function of Complex Networks. *SIAM Rev.* **45**, 167–256 (2003).

Author Contribution Statement

Y. L., D. S., H. H., YC. T. and F. C. designed the algorithm. Y. L., C. N., M. P., Z. F. and F. C. validated the algorithm. Y. L., M.P. and F.C. wrote the main manuscript. All authors reviewed the manuscript.

Additional Information

The authors have declared that no competing interests exist.

Figure. 1. Comparison of performance of three methods (ranking DDIs based on frequency: white, based on co-occurrence without random sampling filtering: grey, and based on co-occurrence with random sampling: black) for ibuprofen, warfarin, furosemide and sertraline.

Figure. 2. The social network constructed by selected compounds and proteins for ibuprofen (A), warfarin (B) furosemide (C) and sertraline (D). The proteins and the compounds are shown in grey and white.

Figure 3. Workflow of the algorithm.

Compouds interacted	Frequency	p-value
with ibuproten		
Fluconazole	7	0
Fluvastatin	3	0
Voriconazole	3	0
Digoxin	6	0
Lithium	6	0
Captopril	7	0
Aspirin	87	0
Lisinopril	3	0
Warfarin	15	0
Itraconazole	3	2.22E-16
Compouds interacted	Frequency	p-value
with warfarin		
Miconazole	22	0
Moxifloxacin	7	0
Methyl salicylate	7	0
Tramadol	7	0
Clarithromycin	7	Ô
Terbinafine	6	0
Dulovetine	4	0
Fenofibrate	4	0
Tolterodine	3	0
Pitavastatin	3	0
Compouds interacted	Frequency	n-value
Compouds interacted with furosemide	Frequency	p-value
Compouds interacted with furosemide	Frequency	p-value
Compouds interacted with furosemide Diflunisal	Frequency 3	p-value
Compouds interacted with furosemide Diflunisal Clenbuterol Prohenacid	Frequency 3 3	p-value 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin	Frequency 3 3 21 44	p-value 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Feature	Frequency 3 3 21 44 2	p-value 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Coftgridime	Frequency 3 3 21 44 3 2	p-value 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime	Frequency 3 3 21 44 3 3 7	p-value 0 0 0 0 0 0 0 0 0 2.00E 15
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine	Frequency 3 3 21 44 3 3 7 2	p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Blassulbuterous	Frequency 3 3 21 44 3 3 7 3 7	p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin	Frequency 3 21 44 3 3 7 3 7 8	p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin	Frequency 3 3 21 44 3 3 7 3 7 8	p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency	p-value 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency	p-value 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline	Frequency 3 3 2 1 4 4 3 3 7 3 7 8 Frequency 4	p-value 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 4	p-value 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline linezolid Phenytoin Ammonium Chloride	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 3 3	p-value 0 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline linezolid Phenytoin Ammonium Chloride Selegiline	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 3 4 3 4	p-value 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline linezolid Phenytoin Ammonium Chloride Selegiline Carbamazepine	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 3 4 9	p-value 0 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline linezolid Phenytoin Ammonium Chloride Selegiline Carbamazepine Methadone	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 3 4 9 4	p-value 0 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0 0 0 0 1.76E-13
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline linezolid Phenytoin Ammonium Chloride Selegiline Carbamazepine Methadone pramipexole	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 3 4 9 4 3 3	p-value 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0 0 0 0 0 1.76E-13 3.81E-09
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline linezolid Phenytoin Ammonium Chloride Selegiline Carbamazepine Methadone pramipexole 5-Hydroxytryptophan	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 3 4 9 4 3 3 3	p-value 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0 0 0 0 0 0 0 0 0 0 0
Compouds interacted with furosemide Diflunisal Clenbuterol Probenecid Indomethacin Fentanyl Ceftazidime Cephaloridine Aprotinin Phenylbutazone Warfarin Compouds interacted with sertraline linezolid Phenytoin Ammonium Chloride Selegiline Carbamazepine Methadone pramipexole 5-Hydroxytryptophan aripiprazole	Frequency 3 3 21 44 3 3 7 3 7 8 Frequency 4 4 3 4 9 4 3 3 5	p-value 0 0 0 0 0 0 0 0 3.00E-15 1.07E-13 1.51E-11 2.07E-11 p-value 0 0 0 0 0 0 0 0 0 0 0 0 0

Table 1. Performance of the identified compounds in a top 10 list of results based on cooccurrence with random sampling.

Compounds predicted correctly are in italic and bold.

Drug	Extracted enzyme involved in DDIs	Frequency	p value
	PTGS1 protein, human	5	1.20E-05
Ibuprofen	Cytochrome P-450 CYP2C9	3	7.47E-03
	Aryl Hydrocarbon Hydroxylases	3	1.28E-02
Warfarin	CYP3A4 protein, human	13	0
	Cytochrome P-450 CYP3A	17	0
	Prostaglandin-Endoperoxide Synthases	3	2.32E-11
	PTGS2 protein, human	3	2.32E-11
	Cyclooxygenase 2	3	3.38E-08
	Cytochrome P-450 CYP1A2	5	1.77E-04
	Cytochrome P-450 CYP2D6	5	5.10E-04
	CYP3A protein, human	5	5.65E-04
	Steroid 16-alpha-Hydroxylase	11	4.60E-03
	Steroid Hydroxylases	11	7.25E-03
	Aryl Hydrocarbon Hydroxylases	77	8.92E-03
	CYP2C9 protein, human	67	5.81E-02
	Cytochrome P-450 CYP2C9	67	6.08E-02
	Alanine Transaminase	3	8.32E-02
	Aspartate Aminotransferases	3	8.47E-02
Furosemide	Thromboxane-A Synthase	3	0
	Glutathione Transferase	3	1.78E-15
Sertraline	CYP3A protein, human	8	0
	Mixed Function Oxygenases	14	0
	Cytochrome P-450 Enzyme System	18	0
	Cytochrome P-450 CYP3A	8	0
	Steroid 16-alpha-Hydroxylase	5	0
	Steroid Hydroxylases	5	0
	Aryl Hydrocarbon Hydroxylases	8	0
	Cytochrome P-450 CYP2D6	9	0
	Cytochrome P-450 CYP2C9	4	1.76E-13
	CYP2C9 protein, human	4	1.76E-13
	Cytochrome P-450 CYP1A2	3	2.82E-12
	Cytochrome P-450 CYP2C19	3	4.10E-06
	CYP2C19 protein, human	3	4.10E-06
	Receptor, Serotonin, 5-HT1A	3	6.95E-03

Table 2. Significant proteins identified from substances of MEDLINE for ibuprofen, warfarin, furosemide and sertraline.